Azelaic Acid Sourcing Guide for Formulation Buyers

Quick Answer

Azelaic acid is an attractive specialty ingredient because it sits between a well-known cosmetic active and a regulated topical pharmaceutical ingredient. That position creates a sourcing problem: a marketplace listing may show 99% cosmetic grade, while the formulation team still has to solve identity, solid-state behavior, dispersion, irritation control and the intended market's claim requirements. The product page is only the beginning of the qualification process.

This guide reviews two current Alibaba listings as sourcing leads. It does not treat either page as proof of efficacy, regulatory acceptance or batch quality. The useful buyer question is more specific: what must be confirmed before a white powder labelled azelaic acid can be compared fairly, sampled, and considered for a finished formula?

Lock the Chemical Identity Before Comparing Suppliers

Azelaic acid is also called nonanedioic acid and is associated with CAS 123-99-9. PubChem and specialist chemical references identify the molecular formula as C9H16O4 and the molecular weight as approximately 188.22 g/mol. Those identifiers should appear consistently on the quotation, specification, COA, SDS, package label and sample record.[1,2]

The identity check is not a formality. The marketplace category may contain azelaic acid, azelaic acid derivatives, salts, blends, or pages where attributes have been copied from another ingredient. The buyer should compare the CAS number with the formula and the stated appearance. An inconsistency should be recorded as a hard documentation gap, not silently corrected by the buyer.

The intended role also needs to be written down. Azelaic acid may be considered for cosmetic skin-care development, or it may be discussed in relation to acne or rosacea treatment. Those are not interchangeable claims. Evidence from a pharmaceutical gel does not automatically validate a cosmetic powder, and a cosmetic raw-material page does not establish that the finished product can make a drug claim.

Why the 99 Percent Headline Is Incomplete

A 99% statement can describe a minimum assay, a typical result, or a rounded marketing value. The number becomes meaningful only when the supplier states the method, basis, lot and acceptance limit. Titration, GC, HPLC and other approaches may not answer the same question, particularly when the buyer is evaluating related substances, residual solvents, water or degradation products.

A professional request should ask whether the value is reported on an as-is basis or after drying, whether the method is validated for the material, and whether the result is tied to the lot being quoted. If the supplier provides only a generic certificate with no lot number, treat it as preliminary screening evidence. It should not be used as the incoming specification for a production shipment.

Particle Behavior Can Decide Whether the Formula Works

Azelaic acid is a solid dicarboxylic acid, not a universally water-soluble powder. Reference data describe limited water solubility at room temperature and better solubility in selected organic solvents. The exact behavior in a cosmetic system depends on temperature, solvent or emollient choice, pH, concentration, particle size, mixing energy and the cooling path. A supplier's statement that the powder is easy to use is therefore not a transferable specification.[3]

Particle size matters even when the assay is identical. A finer powder may disperse more rapidly, but it can also dust more easily, agglomerate, or change the rheology of a suspension. A coarser crystalline material may be easier to handle but harder to incorporate uniformly. If the supplier does not state D10, D50, D90, sieve residue or another particle descriptor, the buyer should not invent one. Instead, request the available measurement and record it as not stated when unavailable.

The formulation team should decide what kind of system is being developed before asking for a sample. An anhydrous suspension, emulsion, gel, cream or hydroalcoholic product can require a different grade or process. A sample test in water may show sediment, but that result alone does not tell the buyer whether the intended emulsion or suspension will be acceptable. Use the real vehicle, target concentration, mixing order, temperature and storage conditions.

Solubility, pH and Irritation Need to Be Reviewed Together

Azelaic acid has two carboxylic acid groups, so pH can change its ionization and apparent solubility. Raising pH may improve the amount held in an aqueous phase, but it can also change skin feel, preservative behavior, compatibility with polymers and the final product's irritation profile. Neutralization with a base is not a free improvement: it changes the chemical form and may affect the specification or the sensory character of the formula.[3]

The sample protocol should therefore include a defined pH range and a record of whether the material is truly dissolved, finely dispersed, or present as a suspension. These states should not be described with the same word. A clear solution, a stable translucent dispersion, and a temporary mixture that settles after cooling are different development outcomes.

Published topical studies can inform the formulation team about concentration and vehicle, but they do not turn a raw-material listing into a validated finished product. If the formula is intended for sensitive or acne-prone skin, evaluate irritation and tolerability under the actual use conditions. Do not copy a prescription gel concentration into a cosmetic specification without checking the target market, claim category and finished-product test plan.[4,5]

What to Request in the Technical Package

Request the same documents from both suppliers so the comparison is based on equivalent evidence. The core package should include:

• A current specification naming azelaic acid, CAS 123-99-9, formula, appearance, assay limit and the analytical methods used.
• A lot-specific COA with the actual result, lot number, test date, acceptance limits, and signer or laboratory information.
• Identity evidence such as FTIR, GC, HPLC, melting range, or another method appropriate to the supplied grade.
• Particle-size or sieve information, with the measurement method and sample preparation if available.
• Water or loss-on-drying, residual solvents, related substances, elemental impurities and microbiological data where the product risk assessment requires them.
• SDS, storage guidance, package material, shelf-life or retest approach, and instructions after opening.
• Manufacturing or repacking status, origin of the material, batch traceability, and confirmation that the sample grade matches the production grade.
• A technical explanation of recommended incorporation conditions that is clearly labelled as supplier guidance, not an industry-wide rule.

The buyer should also ask whether the 99% claim is measured by GC or another method, whether water is included in the basis, and whether the supplier controls the particle-size distribution. If the answer is available on request, ask for the current document before placing a larger order. A missing field should remain unresolved rather than being filled with a typical value from another vendor.

Regulatory and Claim Boundaries Are Part of Procurement

Azelaic acid appears in both cosmetic and medicinal discussions, which makes product positioning important. The target market, finished-product category, concentration, packaging and claim wording can determine whether the formula is treated as a cosmetic, an over-the-counter product, or a medicinal product. A supplier's use label cannot settle that question.[6,7]

For the European Union, the buyer should review the current Cosmetic Products Regulation and the product's intended claims. For the United States, the relevant FDA framework for a finished acne treatment is different from a cosmetic brightening or skin-conditioning product. Other markets may use their own positive lists, notification systems or drug pathways. The regulatory file should be prepared for the actual destination market rather than copied from a general global sales sheet.

Keep four evidence categories separate: raw-material identity, batch quality, finished-formula performance and regulatory status. A COA can support the first two only within its stated scope. A formulation study supports the third. A regulatory assessment supports the fourth. Combining them into a single claim such as 99% cosmetic grade for acne treatment creates a conclusion that the evidence does not support.

Commercial Sourcing Options

The sourcing options below are listed for review. They are sourcing routes for the exact listings reviewed in this article. They do not independently prove assay, particle-size control, regulatory acceptance or finished-product efficacy.

How to Read the Two Current Listings

The Azelaic acid 99% cosmetic grade listing is a useful starting point because the visible page identifies CAS 123-99-9, a 99% claim, a white crystalline powder, sample availability, COA availability and a supplier profile with a longer visible operating history. Those details make it a sensible documentation benchmark. They remain marketplace statements, however. The buyer should request the current lot COA and confirm whether the supplier manufactures the material, repacks it, or sources it from another producer.

The Azelaic acid bulk 99% listing provides an independent comparison with the same CAS and a 99% cosmetic-grade description. Its stated MOQ and package information are useful for planning a sample-to-bulk discussion. The key qualification question is whether the specification behind the listing includes particle information, identity evidence, and actual impurity or moisture limits. A clean title does not answer those questions.

The two listings should be compared using the same RFQ. Do not compare one supplier's stated 99% purity with another supplier's 99% specification until the methods and bases are known. Do not treat a low MOQ, a sample offer, or an attractive page rating as proof of the technical grade. Commercial convenience matters, but it should be scored after identity and documentation gates are passed.

Supplier age is a weighted signal, not an absolute rule. A supplier with seven or eight years of visible history may offer useful continuity, while a younger supplier can still qualify if the manufacturing explanation, documents, sample, response quality and lot traceability are strong. A long profile cannot compensate for a formula mismatch or an unclear assay method.

A Practical Sample-to-Bulk Qualification Sequence

Send the same written request to both suppliers. Ask for the current specification, recent lot COA, SDS, particle-size information, package details, storage conditions, and manufacturing or repacking status. Ask the supplier to state which document will govern the production shipment and whether the sample can be linked to a current lot.

On receipt, photograph the package and label, record the lot number, inspect the powder for color and agglomeration, and note the opening condition. Then test the material in the intended vehicle. Record pH, temperature, mixing order, mixing time, appearance after cooling, sedimentation, crystal formation and changes during accelerated storage. Keep an identity test and a prototype observation in separate sections of the report.

If the material is used in an emulsion or gel, assess whether the active remains evenly distributed after storage and whether the process creates visible crystals or gritty texture. If it is used in a suspension, define the acceptable settling and redispersion behavior. These observations should be tied to the lot number and formula version so that a later change in supplier or particle size can be investigated rather than mistaken for a formulation failure.

Approve a production supplier only when the documents, sample and commercial offer describe the same material. Save the raw product page, supplier page, quotation, specification, COA, sample notes, test results and decision. Marketplace attributes can change; a controlled internal record preserves the basis for the decision.

A separate supplier-level sourcing link is not inserted until the exact supplier tracking URL is generated and verified. A product listing and a supplier storefront are different routes and are not interchangeable. The raw supplier page for the first candidate (Xi'an Pincredit Bio-Tech) is retained as a supplier reference for the RFQ and future supplier-level sourcing link generation, but it is not used as a tracking link here.

Bottom Line for a Buyer

Azelaic acid is not difficult to identify, but it is easy to oversimplify. The CAS number and a 99% headline establish a starting point; they do not establish particle behavior, dispersion, irritation profile, finished-product performance or market authorization. Those questions become more important when a buyer moves from a small sample to a repeatable production process.

Use the two listings as controlled sourcing leads. Confirm the method and lot evidence, request particle information, test the exact grade in the intended vehicle, and keep cosmetic evidence separate from medicinal claims. The better supplier is the one that can keep identity, batch documents, sample behavior and commercial terms consistent from the first RFQ through the production order.

References

1. National Center for Biotechnology Information. PubChem Compound Summary: Azelaic acid, CID 2266. https://pubchem.ncbi.nlm.nih.gov/compound/Azelaic-acid
2. Tokyo Chemical Industry. Azelaic Acid CAS 123-99-9 technical data. https://www.tcichemicals.com/OP/en/p/A1318
3. Effect of ionization and vehicle on skin absorption and penetration of azelaic acid. https://pubmed.ncbi.nlm.nih.gov/15556711/
4. Azelaic acid gel 15% in the management of papulopustular rosacea. https://pubmed.ncbi.nlm.nih.gov/21453554/
5. The use of topical azelaic acid for common skin disorders other than inflammatory rosacea. https://pubmed.ncbi.nlm.nih.gov/7737781/
6. European Union. Regulation (EC) No 1223/2009 on cosmetic products. https://eur-lex.europa.eu/eli/reg/2009/1223/2026-05-18/eng
7. U.S. Food and Drug Administration. Over-the-Counter Human Drugs. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D